口服抗凝药潜在药物相互作用致血栓栓塞事件的药物流行病学筛查
本研究利用Optum临床信息学数据库2000-2016年数据,对口服抗凝药使用者进行高通量药物流行病学筛查,采用自身对照病例系列设计,以普伐他汀为阴性对照,筛选与血栓栓塞住院风险升高相关的口服抗凝药- precipitant药物对。共筛查1622对药物组合,发现226对(14%)风险显著升高,经阴性对照校正后得到69个潜在DDI信号,其中33个(48%)未在Lexicomp和/或Micromedex数据库中记录,华法林相关信号多于DOACs。
要点
- 共筛查1622对口服抗凝药-合并用药组合,226对(14%)与血栓栓塞风险显著升高相关。
- 经普伐他汀阴性对照校正后得到69个潜在DDI信号,33个(48%)未在Lexicomp和/或Micromedex中记录。
- 华法林相关DDI信号数量多于直接口服抗凝药(DOACs)。
核心结论
- 口服抗凝药与多种合并用药存在潜在DDI信号,部分信号未被现有DDI知识库收录,需未来病因学研究验证。
研究设计与样本
- 高通量药物流行病学筛查研究,使用Optum Clinformatics Data Mart 2000-2016年数据。
- 采用自身对照病例系列设计,纳入至少有一次血栓栓塞事件住院的成人口服抗凝药(华法林、达比加群、利伐沙班、阿哌沙班、艾多沙班)使用者。
- 使用条件Poisson回归估计率比,比较每个抗凝药- precipitant对中暴露与未暴露时间的血栓栓塞住院率。
- 以普伐他汀作为阴性对照目标药物以减少适应证混杂,并用半贝叶斯收缩调整多重估计。
主要发现
- 共筛查1622对口服抗凝药- precipitant药物对,识别出226对(14%)与血栓栓塞风险显著升高相关。
- 经普伐他汀阴性对照校正后,潜在DDI信号减少至69个。
- 69个信号中33个(48%)未在Lexicomp和/或Micromedex数据库中记录。
- 华法林相关DDI信号多于DOACs。
临床怎么用
- 临床应关注口服抗凝药与合并用药的潜在相互作用,尤其是未收录于常规DDI知识库的组合。
- 对华法林使用者应加强合并用药审查,因其潜在DDI信号更多。
局限性
- 研究为筛查性质,发现的DDI信号需未来病因学研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug-drug interactions (DDIs) with oral anticoagulants may lead to under-anticoagulation and increased risk of thromboembolism. Although warfarin is susceptible to numerous DDIs, few studies have examined DDIs resulting in thromboembolism or those involving direct-acting oral anticoagulants (DOACs). We aimed to identify medications that increase the rate of hospitalization for thromboembolic events when taken concomitantly with oral anticoagulants. We conducted a high-throughput pharmacoepidemiologic screening study using Optum Clinformatics Data Mart, 2000-2016. We performed self-controlled case series studies among adult users of oral anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban) with at least one hospitalization for a thromboembolic event. Among eligible patients, we identified all oral medications frequently co-prescribed with oral anticoagulants as potential interacting precipitants. Conditional Poisson regression was used to estimate rate ratios comparing precipitant exposed vs. unexposed time for each anticoagulant-precipitant pair. To minimize within-person confounding by indication for the precipitant, we used pravastatin as a negative control object drug. Multiple estimation was adjusted using semi-Bayes shrinkage. We screened 1,622 oral anticoagulant-precipitant drug pairs and identified 226 (14%) drug pairs associated with statistically significantly elevated risk of thromboembolism. Using pravastatin as the negative control object drug, this list was reduced to 69 potential DDI signals for thromboembolism, 33 (48%) of which were not documented in the DDI knowledge databases Lexicomp and/or Micromedex. There were more DDI signals associated with warfarin than DOACs. This study reproduced several previously documented oral anticoagulant DDIs and identified potential DDI signals that deserve to be examined in future etiologic studies.
引用
- Zhou M, Leonard CE, Brensinger CM, et al. Pharmacoepidemiologic Screening of Potential Oral Anticoagulant Drug Interactions Leading to Thromboembolic Events. Clin Pharmacol Ther. 2020. PMID: 32275326. doi:10.1002/cpt.1845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。